These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846 [No Abstract] [Full Text] [Related]
6. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798 [TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328 [TBL] [Abstract][Full Text] [Related]
8. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803 [TBL] [Abstract][Full Text] [Related]
9. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258 [TBL] [Abstract][Full Text] [Related]
10. Screening and monitoring of the BTK Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713 [TBL] [Abstract][Full Text] [Related]
11. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420 [TBL] [Abstract][Full Text] [Related]
12. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Huang X; Qiu L; Jin J; Zhou D; Chen X; Hou M; Hu J; Hu Y; Ke X; Li J; Liang Y; Liu T; Lv Y; Ren H; Sun A; Wang J; Zhao C; Salman M; Sun S; Howes A; Wang J; Wu P; Li J Cancer Med; 2018 Apr; 7(4):1043-1055. PubMed ID: 29533000 [TBL] [Abstract][Full Text] [Related]
13. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Byrd JC; Furman RR; Coutre SE; Burger JA; Blum KA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Shaw Y; Bilotti E; Zhou C; James DF; O'Brien S Blood; 2015 Apr; 125(16):2497-506. PubMed ID: 25700432 [TBL] [Abstract][Full Text] [Related]
14. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Burger JA; Barr PM; Robak T; Owen C; Ghia P; Tedeschi A; Bairey O; Hillmen P; Coutre SE; Devereux S; Grosicki S; McCarthy H; Simpson D; Offner F; Moreno C; Dai S; Lal I; Dean JP; Kipps TJ Leukemia; 2020 Mar; 34(3):787-798. PubMed ID: 31628428 [TBL] [Abstract][Full Text] [Related]